2'-HYDROXY-2,4,4',5,6'-PENTAMETHOXYCHALCONE manufacturers
- Rubone
-
- $297.00
-
2026-04-20
- CAS:73694-15-2
- Purity: 98.92%
- Supply Ability: 10g
|
| | 2'-HYDROXY-2,4,4',5,6'-PENTAMETHOXYCHALCONE Basic information |
| Product Name: | 2'-HYDROXY-2,4,4',5,6'-PENTAMETHOXYCHALCONE | | Synonyms: | 2'-HYDROXY-2,4,5,4',6'-PENTAMETHOXYCHALCONE;Rubone~2,4,5-Trimethoxybenzylidene(2-hydroxy-4,6-dimethoxyacetophenone);2,4,5-Trimethoxybenzylidene(2-hydroxy-4,6-dimethoxyacetophenone);2-Propen-1-one, 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(2,4,5-trimethoxyphenyl)-, (2E)-;Rubone >=98% (HPLC);2'-Hydroxy-2,4,4',5,6'-pentamethoxychalcone;2'-Hydroxy -2,4',4,5,6'- Penta methoxy Chalcone;RUBONE | | CAS: | 73694-15-2 | | MF: | C20H22O7 | | MW: | 374.38 | | EINECS: | | | Product Categories: | | | Mol File: | 73694-15-2.mol |  |
| | 2'-HYDROXY-2,4,4',5,6'-PENTAMETHOXYCHALCONE Chemical Properties |
| Boiling point | 586.1±50.0 °C(Predicted) | | density | 1.214±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: 2mg/mL, clear (warmed) | | pka | 6.79±0.40(Predicted) | | form | powder | | color | yellow to orange | | InChI | 1S/C20H22O7/c1-23-13-9-15(22)20(19(10-13)27-5)14(21)7-6-12-8-17(25-3)18(26-4)11-16(12)24-2/h6-11,22H,1-5H3/b7-6+ | | InChIKey | VHCQVGQULWFQTM-VOTSOKGWSA-N | | SMILES | O(C)c1c(cc(c(c1)OC)\C=C\C(=O)c2c(cc(cc2O)OC)OC)OC |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | 2'-HYDROXY-2,4,4',5,6'-PENTAMETHOXYCHALCONE Usage And Synthesis |
| Uses | Rubone, a chalcone analog, is a modulator of miR-34a. Rubone upregulates miR-34a expression in a p53 dependent manner, downregulates the downstream target Bcl-2 and Cyclin D1 expression, and suppresses hepatocellular carcinoma (HCC) growth in vivo. Rubone enhances the anticancer effect of Paclitaxel (PTX; HY-B0015) in PTX-resistant prostate cancer cell lines by reversing the expression of miR-34a downstream targets[1][2][3]. | | Definition | ChEBI: Rubone is a member of chalcones. | | Biological Activity | Rubone has strong anticancer activity. Rubone and paclitaxel (PTX) combination therapy retarded cancer cell growth, migration and cancer stem-like cells (CSC) population growth.', 'Rubone is a miR34a modulator th at specifically restores miR34a in hepatocellular carcinoma cells with wild-type or mutated p53. Rubone potently inhibits growth of hepatocellular carcinoma in a mouse xenograft model. Rubone does not effect the growth of nontumorigenic human hepatocytes.', 'Rubone is a miR34a modulator th at specifically restores miR34a in hepatocellular carcinoma cells. | | in vivo | Rubone monotherapy (20 mg/kg loaded PEG-PCD micelles; iv for five doses every other day) or combination therapy with PTX (10 mg/kg for each drug loaded PEG-PCD micelles) significantly upregulates miR-34a expression in tumor. The combination therapy inhibits tumor growth. Rubone monotherapy failed to suppress tumor cell proliferation[3].
| Animal Model: | 8 weeks old male nude mice transfected prostate cancer cells[3] | | Dosage: | 20 mg/kg or 10 mg/kg for each drug (PTX and Rubone) loaded PEG-PCD micelles | | Administration: | Intravenously for five doses every other day | | Result: | Had little effect on body weight loss and inhibited tumor growth.
Monotherapy or combination therapy with PTX significantly upregulated miR-34a expression in tumor.
Alone or with PTX significantly reversed E-cadherin, Cyclin D1, and SIRT1 expression.
|
| | References | [1] Zhangang Xiao, et al. Small molecule targeting miR-34a for cancer therapy. Mol Cell Oncol. 2015 Feb 24;2(1):e977160. DOI:10.4161/23723556.2014.977160
[2] Lu Zhang, et al. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019 Feb 4;38(1):53. DOI:10.1186/s13046-019-1059-5
[3] Di Wen, et al. Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer. Cancer Res. 2017 Jun 15;77(12):3244-3254. DOI:10.1158/0008-5472.CAN-16-2355 |
| | 2'-HYDROXY-2,4,4',5,6'-PENTAMETHOXYCHALCONE Preparation Products And Raw materials |
|